Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Lilly Resubmits Cymbalta(R) Supplemental New Drug Application For Chronic Pain To U.S. Food And Drug Administration
As projected, Eli Lilly and Company (NYSE: LLY) has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA). Lilly"s resubmission is based on a recently completed study in chronic pain due to osteoarthritis, the extension phase of a chronic low back pain study and previously completed studies in pain due to osteoarthritis and chronic low back pain. The application is supported by studies in diabetic peripheral neuropathic pain (DPNP) and fibromyalgia. Don't forget to buy zoloft online no prescription.

Novel Strategy For Treating Obesity Suggested By Creation of Energy-Burning Brown Fat In Mice
Researchers at Dana-Farber Cancer Institute have shown that they can engineer mouse and human cells to produce brown fat, a natural energy-burning type of fat that counteracts obesity. If such a strategy can be developed for use in people, the scientists say, it could open a novel approach to treating obesity and diabetes.

generic viagra online


News of the day
More Than Half Of Primary Care Doctor Grads Are Immigrants
"Nationally, about a quarter of all residency graduates began their medical training abroad. And in primary care - where there is a national shortage of physicians - more than half of all graduates are immigrants," The Concord Monitor reports. "New Hampshire"s primary care doctors are aging, and as they retire, recruiters said they will increasingly be replaced by physicians who began their training outside the country."
Endocrinology

FDA Approves Plan B(R) One-Step, A New One-Pill Emergency Contraceptive

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Plan B® One-Step emergency contraception (levonorgestrel tablet, 1.5 mg). Now, with new Plan B® One-Step, women can help prevent an unintended pregnancy after unprotected sex or contraceptive failure with just one pill in one dose. The FDA is expanding over-the-counter (OTC) access to Plan B® One-Step for consumers age 17 or older; women younger than age 17 will require a prescription. The product will be available at licensed U.S. retail pharmacies within the next month. "As a leader in women"s health, we"re proud to offer women this new, innovative emergency contraceptive option that builds upon the trust that women have come to know with Plan B®," notes Amy Niemann, General Manager, Senior Vice President of Teva Women"s Health. "Emergency contraception is more effective the sooner it"s taken, and with Plan B® One-Step women can now act quickly and take it right away when the unexpected happens." About Plan B® One-Step Plan B® One-Step will be available OTC at the pharmacy for consumers age 17 or older with government-issued proof-of-age identification. Women younger than age 17 will require a prescription to purchase Plan B® One-Step. When taken as directed, within 72 hours (3 days) of unprotected sex or contraceptive failure, Plan B® One-Step is highly effective in reducing the chance of pregnancy. About seven out of eight women who would have gotten pregnant will not become pregnant after taking it. Plan B® One-Step should be taken as soon as possible after unprotected sex-the sooner it is taken, the more effective it will be. Plan B® One-Step will not work if a woman is already pregnant and it will not terminate an existing pregnancy. Teva Pharmaceutical Industries Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009